We analyzed γδ T cells derived from PBMCs of patients with stage IV metastatic melanoma before starting either α-PD-1 monotherapy (pembrolizumab) or α-PD-1/α-CTLA-4 (nivolumab/ipilimumab) combination therapy. This evidence concerns the gene PDCD1 and metastatic melanoma.